A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs IONIS APOA-LRx (Primary)
  • Indications Hyperlipoproteinaemias
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Akcea Therapeutics media release, this trial will support the design of the Phase 3 cardiovascular outcome study (see profile 280650).
    • 30 Mar 2017 According to an Akcea Therapeutics media release, topline data from this trial will br reported in the middle of 2018.
    • 07 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top